Cardioptimus Overview

  • Founded
  • 2012
  • Status
  • Private
  • Latest Deal Type
  • 2ndary - Private

Cardioptimus General Information


Developer of an embolic deflection device designed to aid in transcatheter aortic valve replacement. The company's device would deflect emboli down the descending aorta to prevent neurological dysfunctions such as stroke, enabling doctors to improve patient outcomes during TAVR (transcatheter aortic valve replacement) and cardiac surgery procedures.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Primary Industry
Surgical Devices
Other Industries
Therapeutic Devices
Primary Office
  • 1601 South Providence Road
  • Columbia, MO 65211
  • United States
+1 (417) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Cardioptimus Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Secondary Transaction - Private 01-Oct-2021 00000 Completed Generating Revenue
1. Seed Round 01-Sep-2013 00000 00000 Completed Generating Revenue
To view Cardioptimus’s complete valuation and funding history, request access »

Cardioptimus Executive Team (7)

Name Title Board Seat Contact Info
Raymond Troy Co-Founder & Chief Operating Officer
Raja Gopaldas MD Co-Founder
Kyle Rood Co-Founder & CRO
You’re viewing 3 of 7 executive team members. Get the full list »